By Stephen Nakrosis

Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) said Monday that results from a phase III, randomized, double-blind, multicenter clinical study showed blood-disorder drug Luspatercept "achieved a highly statistically significant improvement in the primary endpoint of erythroid response."

According to the companies, the test results showed a significant reduction in transfusion burden compared to a placebo and the safety profile was generally consistent with previously reported data.

The companies also said "the drug achieved primary and all key secondary endpoints in phase III 'BELIEVE' study in adults with transfusion-dependent beta-thalassemia and all key secondary endpoints in phase III 'BELIEVE' study in adults with transfusion-dependent beta-thalassemia."

The companies plan to submit regulatory applications for Luspatercept in the U.S. and Europe in the first half of 2019.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 09, 2018 18:05 ET (22:05 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.